Report overview
Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.
Osteoporosis may be due to lower than normal peak bone mass and greater than normal bone loss. Bone loss increases after menopause due to lower levels of estrogen. Osteoporosis may also occur due to a number of diseases or treatments including alcoholism, anorexia, hyperthyroidism, surgical removal of the ovaries, and kidney disease. Certain medications increase the rate of bone loss including some antiseizure medications, chemotherapy, proton pump inhibitors, selective serotonin reuptake inhibitors, and steroids. Not enough exercise and smoking are also risk factors. Osteoporosis is defined as a bone density of 2.5 standard deviations below that of a young adult. This is typically measured by dual-energy X-ray absorptiometry at the hip.
This report aims to provide a comprehensive presentation of the global market for Osteoporosis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Osteoporosis Drugs. This report contains market size and forecasts of Osteoporosis Drugs in global, including the following market information:
Global Osteoporosis Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Osteoporosis Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Osteoporosis Drugs companies in 2022 (%)
The global Osteoporosis Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
In Brazil, Osteoporosis Drugs key players include Eli Lilly, Novartis, Pfizer, etc. Global top three manufacturers hold a share over 35%.
In terms of product, Antiresorptive Drugs is the largest segment, with a share over 70%. And in terms of application, the largest application is Female, followed by Male.
We surveyed the Osteoporosis Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Osteoporosis Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Osteoporosis Drugs Market Segment Percentages, by Type, 2022 (%)
Antiresorptive Drugs
Anabolic Drugs
Global Osteoporosis Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Osteoporosis Drugs Market Segment Percentages, by Application, 2022 (%)
Female
Male
Global Osteoporosis Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Osteoporosis Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Osteoporosis Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Osteoporosis Drugs revenues share in global market, 2022 (%)
Key companies Osteoporosis Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Osteoporosis Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
Novartis
Pfizer
Amgen
Merck
Novo nordisk
Actavis
Roche
Outline of Major Chapters:
Chapter 1: Introduces the definition of Osteoporosis Drugs, market overview.
Chapter 2: Global Osteoporosis Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Osteoporosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Osteoporosis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Osteoporosis Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
